Clinical Trial Detail

NCT ID NCT01253460
Title Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

CLL/SLL

Therapies

Cyclophosphamide

Rituximab + Sapacitabine

Age Groups: adult

No variant requirements are available.